Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital

Hui-min Xu; Hong-wen Cai; Hai-bin Dai; Xiao-feng Yan; Quan Zhou; Geng Xu; Zhao-quan Huang; Wei Mao

doi:10.1007/s11655-013-1663-8

Your Location：

Home >

Browse articles >

Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital

Updated：2021-08-27

- Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital
- Chinese Journal of Integrative Medicine Vol. 20, Issue 5, Pages: 375-380(2014)
- Affiliations：
  
  1. Department of Pharmacy, the Second Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,China
  2. Department of Cardiovascular Medicine, the First Affiliated Hospital, Zhejiang Chinese Medical University,Hangzhou,China
  3. Department of Cardiovascular Medicine, the Second Affiliated Hospital, School of Medicine, Zhejiang University,Hangzhou,China
- Author bio：
- Funds：
  
  Supported by the grant from Special Fund for Hospital Pharmacy Research of the Zhejiang Pharmaceutical Society (No. 2011ZYY01);These authors contributed equally to this work
- DOI：10.1007/s11655-013-1663-8
  CLC：
- Published：2014，
  
  Published Online：23 January 2014，
Scan for full text
Xu, Hm., Cai, Hw., Dai, Hb. et al. Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital., Chin. J. Integr. Med. 20, 375–380 (2014). https://doi.org/10.1007/s11655-013-1663-8

Hui-min Xu, Hong-wen Cai, Hai-bin Dai, et al. Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital. [J]. Chinese Journal of Integrative Medicine 20(5):375-380(2014)
Xu, Hm., Cai, Hw., Dai, Hb. et al. Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital., Chin. J. Integr. Med. 20, 375–380 (2014). https://doi.org/10.1007/s11655-013-1663-8 DOI：

Hui-min Xu, Hong-wen Cai, Hai-bin Dai, et al. Use of evidence-based pharmacotherapy for secondary prevention of coronary heart disease: A Chinese medicine hospital versus a general hospital. [J]. Chinese Journal of Integrative Medicine 20(5):375-380(2014) DOI： 10.1007/s11655-013-1663-8.

摘要

To determine differences in adherence to secondary prevention guidelines (pharmacological interventions) among coronary heart disease (CHD) patients between a Chinese medicine (CM) hospital and a general hospital in a Chinese city. Medical records of 200 patients consecutively discharged from the CM hospital and the general hospital for CHD were reviewed to determine the proportions of eligible patients who received antiplatelet agents

β-blockers

angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) and statins at discharge. The effects of patient characteristics and hospital type on the use of these medicines were estimated using logistic regression models. Patients discharged from the CM hospitals were older; more likely females; had greater history of hyperlipidemia

cerebrovascular diseases and less smoker (P<0.01 or P<0.05). They were less likely to receive coronary angiography and percutaneous coronary intervention

and had a longer length of stay than those discharged from the general hospital (P<0.01 or P<0.05). There were no significant differences in antiplatelet agents (96% vs. 100%

P=0.121) or statins (97.9% vs. 100%

P=0.149) use between the CM hospital and the general hospital. In multivariable analyses that adjusted for patient characteristics and hospital type

there was no significant difference in use of β-blockers between the CM hospital and the general hospital. In contrast

patients discharged from the CM hospital were less likely to receive ACE inhibitors/ARBs compared with those discharged from the general hospital (odds ratio: 0.3

95% confidence interval: 0.105–0.854). In this study

the CM hospital provides the same quality of care in CHD for prescribing evidence-based medications at discharge compared with another general hospital except for ACE inhibitors/ARBs use.

Abstract

β-blockers

cerebrovascular diseases and less smoker (P<0.01 or P<0.05). They were less likely to receive coronary angiography and percutaneous coronary intervention

and had a longer length of stay than those discharged from the general hospital (P<0.01 or P<0.05). There were no significant differences in antiplatelet agents (96% vs. 100%

P=0.121) or statins (97.9% vs. 100%

P=0.149) use between the CM hospital and the general hospital. In multivariable analyses that adjusted for patient characteristics and hospital type

there was no significant difference in use of β-blockers between the CM hospital and the general hospital. In contrast

patients discharged from the CM hospital were less likely to receive ACE inhibitors/ARBs compared with those discharged from the general hospital (odds ratio: 0.3

95% confidence interval: 0.105–0.854). In this study

the CM hospital provides the same quality of care in CHD for prescribing evidence-based medications at discharge compared with another general hospital except for ACE inhibitors/ARBs use.

关键词

coronary diseasedrugssecondary preventionChinese Medicine

Keywords

coronary diseasedrugssecondary preventionChinese Medicine

references

National Center for Cardiovascular Diseases of China. Report on cardiovascular diseases in China (2010). Beijing: Encyclopedia of China Publishing House; 2011:1.

Menzin J, Wygant G, Hauch O, Jackel J, Friedman M. One-year costs of ischemic heart disease among patients with acute coronary syndromes: findings from a multi-employer claims database. Curr Med Res Opin 2008;24:461–468.

Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363–2372.

Smith SC Jr, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011;124:2458–2473.

The Cardiovascular Branch of Chinese Medical Association, the Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and management of patients with unstable angina/non ST-segment elevation myocardial infarction. Chin J Cardiol (Chin) 2007;35:295–304.

The Cardiovascular Branch of Chinese Medical Association, the Editorial Board of Chinese Journal of Cardiology. Chinese guidelines for the diagnosis and management of patients with ST-segment elevation myocardial infarction. Chin J Cardiol (Chin) 2010;38:675–690.

Bailey TC, Noirot LA, Blickensderfer A, Rachmiel E, Schaiff R, Kessels A, et al. An intervention to improve secondary prevention of coronary heart disease. Arch Intern Med 2007;167:586–590.

Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–1243.

Hesketh T, Zhu WX. Health in China. Traditional Chinese medicine: one country, two systems. BMJ 1997;315:115–117.

Harmsworth K, Lewith GT. Attitudes to traditional Chinese medicine amongst Western trained doctors in the People’s Republic of China. Soc Sci Med 2001;52:149–153.

Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605–613.

McLaughlin TJ, Soumerai SB, Willison DJ, Gurwitz JH, Borbas C, Guadagnoli E, et al. Adherence to national guidelines for drug treatment of suspected acute myocardial infarction: evidence for undertreatment in women and the elderly. Arch Intern Med 1996;156:799–805.

Vermeer NS, Bajorek BV. Utilization of evidence-based therapy for the secondary prevention of acute coronary syndromes in Australian practice. J Clin Pharm Ther 2008;33:591–601.

Qiu J. Traditional medicine: a culture in the balance. Nature 2007;448:126–128.

Xu J, Yang Y. Traditional Chinese medicine in the Chinese health care system. Health Policy 2009;90:133–139.

Tickoo S, Fonarow GC, Hernandez AF, Liang L, Cannon CP. Weekend/holiday versus weekday hospital discharge and guideline adherence (from the American Heart Association’s Get with the Guidelines—Coronary Artery Disease database). Am J Cardiol 2008;102:663–667.

Ying F, Liu HX, Shang JJ, Zhou Q. A comparative analysis of clinical feature and therapeutic status of in-patients with acute myocardial infarction between traditional Chinese medicine and Western medicine third class hospitals in Beijing area in 2005. Chin J Tradit West Crit Care (Chin) 2009;16:206–210.

Bi Y, Gao R, Patel A, Su S, Gao W, Hu D, et al. Evidence-based medication use among Chinese patients with acute coronary syndromes at the time of hospital discharge and 1 year after hospitalization: results from the Clinical Pathways for Acute Coronary Syndromes in China (CPACS) study. Am Heart J 2009;157:509–516 e501.

Liu HX, Wang SR, Lei Y, Shang JJ. Characteristics and advantages of traditional Chinese medicine in the treatment of acute myocardial infarction. J Tradit Chin Med 2011;31:269–272.

FULL TEXT LINK

More>

Views

730

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Future view and development of immunology: Exploring the immunology based on Chinese medicine and culture

Cost-effectiveness analysis of combined Chinese medicine and Western medicine for ischemic stroke patients

Objective tongue inspection on 142 liver cancer patients with damp-heat syndrome

Effect of Ermiao Recipe (二妙方) with medicinal guide Angelicae Pubescentis Radix on promoting the homing of bone marrow stem cells to treat cartilage damage in osteoarthritis rats

Effects of Jianpi Jiedu Recipe (健脾解毒方) on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer

Related Author

No data

Related Institution

Georg-August-Universität Göttingen, Göttingen

The Key Laboratory of Geriatrics, Beijing Hospital and Beijing Institute of Geriatrics’ Ministry of Public Health

Medical Informatics Center, Peking University

Department of Hospital Management, Peking University Health Science Center, Peking University

Neurology Department of Peking University Third Hospital, Peking University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰